{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:13:58Z","timestamp":1792646038091,"version":"4.5.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaso-occlusive crisis (VOC) is the primary cause of morbidity and hospitalization in sickle cell disease (SCD); however, only 4 therapies (hydroxyurea, l-glutamine, crizanlizumab, and voxeletor) are currently approved in SCD. These agents limit the duration, severity, and frequency of crises. Activation of coagulation is a hallmark of SCD. Studies in animal models of SCD have shown that coagulation contributes to the chronic inflammation and end-organ damage associated with the disease; however, it is unknown whether coagulation directly contributes to the microvascular stasis that causes VOC. Herein, we demonstrate that inhibition of tissue factor (TF) and the downstream coagulation proteases factor Xa and thrombin significantly attenuates heme-induced microvascular stasis in mouse models of VOC. Pharmacologic inhibition of the principal thrombin receptor, protease activated receptor-1 (PAR-1), as well as deficiency of PAR-1 in all nonhematopoietic cells, also reduces stasis in sickle mice. PAR-1 deficiency was associated with reduced endothelial von Willebrand factor expression, which has been shown to mediate microvascular stasis. In addition, TF inhibition reduces lung vaso-occlusion in sickle mice mediated by arteriolar neutrophil-platelet microemboli. In sum, these results suggest that prophylactic anticoagulation might attenuate the incidence of VOC.<\/jats:p>","DOI":"10.1182\/blood.2019003543","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T10:06:01Z","timestamp":1579860361000},"page":"1783-1787","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-7847","authenticated-orcid":false,"given":"Erica M.","family":"Sparkenbaugh","sequence":"first","affiliation":[{"name":"UNC Blood Research Center, Division of Hematology\/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Brzoska","sequence":"first","affiliation":[{"name":"Pittsburgh Heart, Lung and Blood Vascular Medicine Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobin","family":"Wang","sequence":"first","affiliation":[{"name":"UNC Blood Research Center, Division of Hematology\/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-0831","authenticated-orcid":false,"given":"Gregory M.","family":"Vercellotti","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-4304","authenticated-orcid":false,"given":"Nigel S.","family":"Key","sequence":"first","affiliation":[{"name":"UNC Blood Research Center, Division of Hematology\/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7568-5719","authenticated-orcid":false,"given":"Prithu","family":"Sundd","sequence":"first","affiliation":[{"name":"Pittsburgh Heart, Lung and Blood Vascular Medicine Institute and"},{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-2752","authenticated-orcid":false,"given":"John D.","family":"Belcher","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-7135","authenticated-orcid":false,"given":"Rafal","family":"Pawlinski","sequence":"first","affiliation":[{"name":"UNC Blood Research Center, Division of Hematology\/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2020051411242877100_B1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/jth.13717","article-title":"Prothrombotic aspects of sickle cell disease","volume":"15","author":"Sparkenbaugh","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020051411242877100_B2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol"},{"issue":"17","key":"2020051411242877100_B3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2018-03-822593","article-title":"How I diagnose and treat venous thromboembolism in sickle cell disease","volume":"132","author":"Shet","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020051411242877100_B4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-04-424143","article-title":"Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease","volume":"120","author":"Chantrathammachart","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020051411242877100_B5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020051411242877100_B6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2014.114728","article-title":"Excess of heme induces tissue factor-dependent activation of coagulation in mice","volume":"100","author":"Sparkenbaugh","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"2020051411242877100_B7","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2004-02-0713","article-title":"The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo","volume":"104","author":"Embury","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2020051411242877100_B8","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2004-07-2698","article-title":"Differential regulation of endothelial exocytosis of P-selectin and von Willebrand factor by protease-activated receptors and cAMP","volume":"107","author":"Cleator","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2020051411242877100_B9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2020051411242877100_B10","doi-asserted-by":"crossref","first-page":"e89761","DOI":"10.1172\/jci.insight.89761","article-title":"Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli","volume":"2","author":"Bennewitz","year":"2017","journal-title":"JCI Insight"},{"issue":"24","key":"2020051411242877100_B11","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1073\/pnas.89.24.12155","article-title":"High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia","volume":"89","author":"Fabry","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2020051411242877100_B12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2020051411242877100_B13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1055\/s-0038-1650676","article-title":"Biological consequences of thrombin receptor deficiency in mice","volume":"76","author":"Darrow","year":"1996","journal-title":"Thromb Haemost"},{"issue":"4","key":"2020051411242877100_B14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028016681129","article-title":"Outcomes of rivaroxaban use in patients with sickle cell disease","volume":"51","author":"Bhat","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"4-5","key":"2020051411242877100_B15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/03630269.2019.1689997","article-title":"Use of direct oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a prospective cohort study of 12 patients","volume":"43","author":"Christen","year":"2019","journal-title":"Hemoglobin"},{"issue":"20","key":"2020051411242877100_B16","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1161\/CIRCULATIONAHA.114.015042","article-title":"Efficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack: results from TRA 2\u00b0P-TIMI 50","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"2020051411242877100_B17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.yjmcc.2018.08.008","article-title":"Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity","volume":"122","author":"Antoniak","year":"2018","journal-title":"J Mol Cell Cardiol"},{"issue":"31","key":"2020051411242877100_B18","doi-asserted-by":"crossref","first-page":"21655","DOI":"10.18632\/oncotarget.25069","article-title":"Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice","volume":"9","author":"Waasdorp","year":"2018","journal-title":"Oncotarget"},{"issue":"6801","key":"2020051411242877100_B19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signalling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"issue":"19","key":"2020051411242877100_B20","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"issue":"7570","key":"2020051411242877100_B21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature15367","article-title":"Neutrophil ageing is regulated by the microbiome","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"24","key":"2020051411242877100_B22","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood-2013-05-498311","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"122","author":"Manwani","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2020051411242877100_B23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"4","key":"2020051411242877100_B24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI1509","article-title":"Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents","volume":"101","author":"Koenig","year":"1998","journal-title":"J Clin Invest"},{"issue":"6","key":"2020051411242877100_B25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood.V98.6.1955","article-title":"P-selectin mediates the adhesion of sickle erythrocytes to the endothelium","volume":"98","author":"Matsui","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2020051411242877100_B26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/ajh.23147","article-title":"A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease","volume":"87","author":"Kutlar","year":"2012","journal-title":"Am J Hematol"},{"issue":"5","key":"2020051411242877100_B27","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion","volume":"175","author":"Telen","year":"2016","journal-title":"Br J Haematol"},{"key":"2020051411242877100_B28","unstructured":"Karolinksa Development\n          . Karolinska Development\u2019s portfolio company Modus Therapeutics announces results from a phase 2 study of sevuparin in patients with sickle cell disease. Available at: https:\/\/www.globenewswire.com\/news-release\/2019\/05\/13\/1822594\/0\/en\/Karolinska-Development-s-portfolio-company-Modus-Therapeutics-announces-results-from-a-Phase-2-study-of-sevuparin-in-patients-with-sickle-cell-disease.html. Accessed 30 November 2019."},{"key":"2020051411242877100_B29","unstructured":"Pfizer. Pfizer announces phase 3 top-line results for rivipansel in patients with sickle cell disease experiencing a vaso-occlusive crisis. Available at: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis. Accessed 30 November 2019."},{"issue":"5","key":"2020051411242877100_B30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/20\/1783\/1728289\/bloodbld2019003543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/20\/1783\/1728289\/bloodbld2019003543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:38:14Z","timestamp":1589503094000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/20\/1783\/440592\/Thrombin-activation-of-PAR1-contributes-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003543","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}